Insider Selling: Hemostemix Inc. (CVE:HEM) Director Sells 332,500 Shares of Stock

Hemostemix Inc. (CVE:HEM) Director Thomas Smeenk sold 332,500 shares of Hemostemix stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of C$0.07, for a total value of C$21,612.50. Following the completion of the sale, the director now directly owns 93 shares of the company’s stock, valued at C$6.05. The trade was a 0.00 % decrease in their ownership of the stock.

Thomas Smeenk also recently made the following trade(s):

• On Wednesday, August 21st, Thomas Smeenk purchased 2,000 shares of Hemostemix stock. The stock was acquired at an average price of C$0.04 per share, with a total value of C$80.00.

Hemostemix Trading Down 14.3 %

CVE:HEM traded down C$0.01 during mid-day trading on Tuesday, hitting C$0.06. The stock had a trading volume of 523,322 shares, compared to its average volume of 96,435. Hemostemix Inc. has a twelve month low of C$0.04 and a twelve month high of C$0.12. The stock has a 50-day simple moving average of C$0.07 and a two-hundred day simple moving average of C$0.06. The company has a market capitalization of C$5.23 million, a PE ratio of -3.00 and a beta of 0.15.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.